Deal typeTransaction Services
IndustryHealthcare
Client nameLifco AB
The transaction team from the Deal Advisory division, led by Dr Steffen Eube and Felix Fries, supported Lifco with the implementation of a red flag financial due diligence.
Karl Kaps, based in Aßlar, Germany, specialises in the development, manufacture and distribution of high-quality microscopes for medical fields such as dentistry, ENT, ophthalmology and gynaecology, as well as for industrial applications. The portfolio is complemented by sports optics and accessories. With this 100% acquisition, Lifco is expanding its portfolio and value creation depth. Lifco is taking over all of Karl Kaps' activities, including its approximately 30 employees.
Lifco is a group of companies that invests in market-leading niche companies across Europe on a long-term basis without reselling them. Lifco's philosophy is based on a focus on the long-term development of its companies and on strong entrepreneurial responsibility on the part of its companies. In 2024, the Lifco Group consisted of 257 companies in 34 countries with sales of SEK 26.1 billion and an EBITA margin of 22.6%.
Karl Kaps, based in Aßlar, Germany, specialises in the development, manufacture and distribution of high-quality microscopes for medical fields such as dentistry, ENT, ophthalmology and gynaecology, as well as for industrial applications. The portfolio is complemented by sports optics and accessories. With this 100% acquisition, Lifco is expanding its portfolio and value creation depth. Lifco is taking over all of Karl Kaps' activities, including its approximately 30 employees.
Lifco is a group of companies that invests in market-leading niche companies across Europe on a long-term basis without reselling them. Lifco's philosophy is based on a focus on the long-term development of its companies and on strong entrepreneurial responsibility on the part of its companies. In 2024, the Lifco Group consisted of 257 companies in 34 countries with sales of SEK 26.1 billion and an EBITA margin of 22.6%.